These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 20419486

  • 1. Ivabradine: from molecular basis to clinical effectiveness.
    Riccioni G.
    Adv Ther; 2010 Mar; 27(3):160-7. PubMed ID: 20419486
    [Abstract] [Full Text] [Related]

  • 2. Ivabradine: beyond heart rate control.
    Riccioni G, Vitulano N, D'Orazio N.
    Adv Ther; 2009 Jan; 26(1):12-24. PubMed ID: 19165437
    [Abstract] [Full Text] [Related]

  • 3. I(f) inhibition in cardiovascular diseases.
    Thollon C, Vilaine JP.
    Adv Pharmacol; 2010 Jan; 59():53-92. PubMed ID: 20933199
    [Abstract] [Full Text] [Related]

  • 4. Rationale and design of a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction: the morBidity-mortality EvAlUaTion of the I(f) inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction (BEAUTIFUL) study.
    Fox K, Ferrari R, Tendera M, Steg PG, Ford I, BEAUTIFUL Steering Committee.
    Am Heart J; 2006 Nov; 152(5):860-6. PubMed ID: 17070146
    [Abstract] [Full Text] [Related]

  • 5. Characterization of the heart rate-lowering action of ivabradine, a selective I(f) current inhibitor.
    Borer JS, Le Heuzey JY.
    Am J Ther; 2008 Nov; 15(5):461-73. PubMed ID: 18806523
    [Abstract] [Full Text] [Related]

  • 6. Ivabradine: an intelligent drug for the treatment of ischemic heart disease.
    Riccioni G.
    Molecules; 2012 Nov 16; 17(11):13592-604. PubMed ID: 23159921
    [Abstract] [Full Text] [Related]

  • 7. Heart rate in ischemic heart disease. The innovation of ivabradine: more than pure heart rate reduction.
    Rosano GM, Vitale C, Volterrani M.
    Adv Ther; 2010 Apr 16; 27(4):202-10. PubMed ID: 20495895
    [Abstract] [Full Text] [Related]

  • 8. Innovation in coronary artery disease and heart failure: clinical benefits of pure heart rate reduction with ivabradine.
    Canet E, Lerebours G, Vilaine JP.
    Ann N Y Acad Sci; 2011 Mar 16; 1222():90-9. PubMed ID: 21434947
    [Abstract] [Full Text] [Related]

  • 9. Ivabradine: pharmacodynamic aspects of its clinical use.
    Stieber J.
    Methods Find Exp Clin Pharmacol; 2008 Oct 16; 30(8):633-41. PubMed ID: 19088948
    [Abstract] [Full Text] [Related]

  • 10. Review of the If selective channel inhibitor ivabradine in the treatment of chronic stable angina.
    Prasad UK, Gray D, Purcell H.
    Adv Ther; 2009 Feb 16; 26(2):127-37. PubMed ID: 19259630
    [Abstract] [Full Text] [Related]

  • 11. Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise.
    Joannides R, Moore N, Iacob M, Compagnon P, Lerebours G, Menard JF, Thuillez C.
    Br J Clin Pharmacol; 2006 Feb 16; 61(2):127-37. PubMed ID: 16433867
    [Abstract] [Full Text] [Related]

  • 12. Focus on ivabradine: a new heart rate-controlling drug.
    Riccioni G.
    Expert Rev Cardiovasc Ther; 2009 Feb 16; 7(2):107-13. PubMed ID: 19210206
    [Abstract] [Full Text] [Related]

  • 13. Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure.
    Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F, Renet S, Lerebours G, Mahlberg-Gaudin F, Thuillez C.
    Circulation; 2004 Apr 06; 109(13):1674-9. PubMed ID: 14981003
    [Abstract] [Full Text] [Related]

  • 14. The importance of reducing heart rate in cardiovascular diseases: effects of Ivabradine.
    Vizzardi E, Bonadei I, D'Aloia A, Del Magro F, Piovanelli B, Bontempi L, Curnis A, Dei Cas L.
    Minerva Med; 2011 Oct 06; 102(5):373-9. PubMed ID: 22193347
    [Abstract] [Full Text] [Related]

  • 15. Ivabradine in chronic stable angina: Effects by and beyond heart rate reduction.
    Camici PG, Gloekler S, Levy BI, Skalidis E, Tagliamonte E, Vardas P, Heusch G.
    Int J Cardiol; 2016 Jul 15; 215():1-6. PubMed ID: 27104917
    [Abstract] [Full Text] [Related]

  • 16. Heart rate as a treatable cardiovascular risk factor.
    Tardif JC.
    Br Med Bull; 2009 Jul 15; 90():71-84. PubMed ID: 19474056
    [Abstract] [Full Text] [Related]

  • 17. Heart rate reduction via selective 'funny' channel blockers.
    Bucchi A, Barbuti A, Baruscotti M, DiFrancesco D.
    Curr Opin Pharmacol; 2007 Apr 15; 7(2):208-13. PubMed ID: 17267284
    [Abstract] [Full Text] [Related]

  • 18. The Role of Ivabradine in the Management of Angina Pectoris.
    Giavarini A, de Silva R.
    Cardiovasc Drugs Ther; 2016 Aug 15; 30(4):407-417. PubMed ID: 27475447
    [Abstract] [Full Text] [Related]

  • 19. Rate control with ivabradine: angina pectoris and beyond.
    Parakh N, Bhargava B.
    Am J Cardiovasc Drugs; 2011 Aug 15; 11(1):1-12. PubMed ID: 21090826
    [Abstract] [Full Text] [Related]

  • 20. Ivabradine: recent and potential applications in clinical practice.
    Riccioni G.
    Expert Opin Pharmacother; 2011 Feb 15; 12(3):443-50. PubMed ID: 21254949
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.